Trial Profile

Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naive patients WIth Neovascular age-related macular degeneration: pilot Study. –

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 May 2016 Status changed from recruiting to completed, as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
17 May 2016 Primary endpoint has not been met. (Variation of choroidal thickness from baseline visit (first ranibizumab injection) to day 15.), as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
17 May 2016 Results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com